Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can they bring Otenaproxesul to market?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(198)
•••
Comment by Pragmatiston Jun 25, 2021 12:47am
161 Views
Post# 33449154

RE:RE:RE:Can they bring Otenaproxesul to market?

RE:RE:RE:Can they bring Otenaproxesul to market?
Bookworm28 wrote: Thanks for the info Pragmatist.

The net can be a real pain at times when doing DD. Found one link that looked pretty legit, but they said Naproxen was under patent until March 2026. Another that said it wasn't under patent. Given the age of Naproxen, your comments, Nuance's investment, I'm thinkin' ATE is fine when it comes to IP considerations. I'd like to have received an email from the Co. to confirm. Not very impressed. with their IR.

Thanks again for your reply. H2 should breath some life into the stock. GLTA.


US4803079A - Controlled release naproxen and naproxen sodium tablets - Google Patents

Ref says the patent expired approx 15 years ago.  I buy my naproxen from a local pharmacy under the generic name " Naproxen".  I find this to be cheaper than the brand names.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities